GRALISE is the first once-daily gabapentinoid that provides
24-hour PHN pain relief with a well-defined safety profile1
Michelle Brown, MD, talks about the unique features of GRALISE.
Watch the videoINDICATIONS AND USAGE
GRALISE is indicated for the management of postherpetic neuralgia (PHN). GRALISE is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
GRALISE is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.
WARNINGS AND PRECAUTIONS
The safety and efficacy of GRALISE in patients with epilepsy has not been studied.
ADVERSE REACTIONS
The most common side effects were dizziness (10.9%) and somnolence (4.5%).
USE IN SPECIFIC POPULATIONS
Reductions in GRALISE dose should be made in patients with age-related compromised renal function.
Reference: 1. GRALISE [prescribing information]. Lake Forest, IL: Assertio Therapeutics, Inc.; December 2012.
